


CD79a Antibody [clone HM47/A9] (V2079)

Catalog No.	Formulation	Size
V2079-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2079-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2079SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V2079IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml


Citations (8)

Bulk quote request


Species Reactivity	Human, Mouse, Rat
Format	Purified
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	HM47/A9
Purity	Protein G affinity chromatography
UniProt	P11912
Localization	Cell surface, cytoplasmic
Applications	Flow Cytometry: 1-2ug/10^6 cells Immunofluorescence: 1-2ug/ml Western Blot: 1-2ug/ml Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Limitations	This CD79a antibody is available for research use only.




Immunofluorescent staining of PFA-fixed human Raji cells with CD79a antibody (clone HM47/A9, green) and Reddot nuclear stain (red).




IHC testing of FFPE human tonsil (10X) stained with CD79a antibody (clone HM47/A9).



Flow cytometry testing of human Raji cells with CD79a antibody (clone HM47/A9); Red=isotype control, Blue= CD79a antibody.



Western blot testing of human Raji cell lysate with CD79a antibody (clone HM47/A9). Expected molecular weight: 25-47 kDa depending on glycosylation level.



SDS-PAGE analysis of purified, BSA-free CD79a antibody (clone HM47/A9) as confirmation of integrity and purity.

Description

CD79a is required in cooperation with CD79b for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro-and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B-cells. [UniProt]

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.

- 1. Staining of FFPE tissues requires boiling sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 min.
- 2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79a protein was used as the immunogen for this antibody.

Storage

Store the CD79a antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Alternate Names

B lymphocyte-specific MB1 protein, B-cell antigen receptor complex-associated protein alpha chain, CD79a molecule immunoglobulin associated alpha, Ig-alpha, IgA, IgM-alpha, Immunoglobulin-associated alpha, Ly54, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein, CD79 antibody, CD79a antibody

References (1)